Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in cancer treatment that can induce durable remission in patients with hematological malignancies who have failed prior therapies. As the use of CAR-T cell therapy increases, treatment-related renal complications deserves careful attention, particularly in patients with a solitary kidney, in whom renal complications may further increase clinical risk. Here, we report the case of a living kidney donor who was diagnosed with diffuse large B-cell lymphoma (DLBCL). After CAR-T cell therapy, the patient developed only mild cytokine release syndrome (CRS), without signs of acute kidney injury or renal impairment, and subsequently achieved a favorable metabolic response approaching complete remission.
Zhang et al. (2026) studied this question.